|
Gil-Lianes J, Gariup G, Iranzo-Fernandez P, Mensa-Vilaro A, Penin-Franch A, Hurtado-Navarro L, Pelegrin P, Arostegui JI. Early-onset recurrent panniculitis as a phenotype of NLRC4-associated autoinflammatory syndrome: Characterization of pathogenicity of the p.Ser445Pro NLRC4 variant. Australas J Dermatol. 2023 May;64(2):260-267. doi: 10.1111/ajd.14005. Epub 2023 Feb 16. PubMed PMID: 36797819.
AÑO: 2023; IF: 2.2
|
36797819
|
Tapiz I Reula AJ, Cochino AV, Martins AL, Angosto-Bazarra D, de Landazuri IO, Mensa-Vilaro A, Cabral M, Baroja-Mazo A, Banos MC, Lobato-Salinas Z, Fabregat V, Plaza S, Yague J, Casals F, Oliva B, Figueiredo AE, Pelegrin P, Arostegui JI. Characterization of Novel Pathogenic Variants Leading to Caspase-8 Cleavage-Resistant RIPK1-Induced Autoinflammatory Syndrome. J Clin Immunol. 2022 Oct;42(7):1421-1432. doi: 10.1007/s10875-022-01298-2. Epub 2022 Jun 18. Erratum In: J Clin Immunol. 2022 Jul 8;: PubMed PMID: 35716229; PubMed Central PMCID: PMC9674708.
AÑO: 2022; IF: 9.1
|
|
Lambris JD, Rosenthal A, Pelegrin P, Tremblay ME, Chen P. The future of neuroimmunology research for CNS disease therapeutics. Trends Pharmacol Sci. 2022 Aug;43(8):611-614. doi: 10.1016/j.tips.2022.06.003. No abstract available. PubMed PMID: 35839748.
AÑO: 2022; IF: 13.8
|
|
Ionescu D, Penin-Franch A, Mensa-Vilaro A, Castillo P, Hurtado-Navarro L, Molina-Lopez C, Romero-Chala S, Plaza S, Fabregat V, Bujan S, Marques J, Casals F, Yague J, Oliva B, Fernandez-Pereira LM, Pelegrin P, Arostegui JI. First Description of Late-Onset Autoinflammatory Disease Due to Somatic NLRC4 Mosaicism. Arthritis Rheumatol. 2022 Apr;74(4):692-699. doi: 10.1002/art.41999. Epub 2022 Feb 14. PubMed PMID: 34672126.
AÑO: 2022; IF: 13.3
|
|
Coll RC, Schroder K, Pelegrin P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci. 2022 Aug;43(8):653-668. doi: 10.1016/j.tips.2022.04.003. Epub 2022 May 3. PubMed PMID: 35513901.
AÑO: 2022; IF: 13.8
|